Gemcitabine plus Capecitabine Combination in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes

Authors:
  • RYRamazan Yildiz
    Ramazan Yildiz
  • AUAytug Uner
    Aytug Uner
  • OEOzlem Er
    Ozlem Er
  • DYDeniz Yamac
    Deniz Yamac
  • NANecati Alkis
    Necati Alkis
  • UCUgur Coskun
    Ugur Coskun
  • CCCelalettin Camci
    Celalettin Camci
  • SBSuleyman Buyukberber
    Suleyman Buyukberber

Abstract
Background: Treatment of patients with metastatic breast cancer (MBC) exposed to anthracyclines and taxanes is challenging. Effective and well-tolerated regimens are required. Gemcitabine plus capecitabine combination was assessed in MBC patients pretreated with anthracyclines and taxanes. Patients and Methods: A total of 31 patients treated between November 2004 and September 2005 were retrospectively evaluated in 4 institutions. The median age was 48 years (range 29–77). The patients were given gemcitabine 1,000 mg/m2 on days 1 and 8, and capecitabine 1,500 mg/m2 twice daily on days 1–14 every 3 weeks. Results: A total of 160 cycles of chemotherapy were administered with a median of 5 cycles per patient (range 2–12). Three patients achieved a partial response (10%) and 8 patients (26%) stable disease. The median time to disease progression was 6 months (95% CI 5–7), with a median survival of 18 months (95% CI 15–21) at a median follow-up of 16 months (range 2–28). One-year and 2-year survival rates were 67 and 28%, respectively. Grade 3–4 toxicities were as follows: neutropenia (n = 11, 35%), nausea and vomiting (n = 4, 13%), hand-foot syndrome (n = 2, 6%), anemia (n = 2, 6%), thrombocytopenia (n = 2, 6%) and asthenia (n = 1, 3%). Conclusion: The combination of gemcitabine plus capecitabine was a tolerable regimen with a mild but comparable survival efficacy to similar regimens in patients with MBC after anthracyclines and taxanes.

This publication has 24 references indexed in Scilit: